Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Voyager Therapeutics, Inc. Banner

Voyager Therapeutics, Inc.

VYGR Stock Analysis

Page title

Section title

About Voyager Therapeutics, Inc.

Biotechnology
Healthcare

Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G...

Voyager Therapeutics, Inc. Key Metrics

Market Cap
$288M
52 Weeks Low
$5.19
52 Weeks High
$11.72
P/B
0.92x
P/E
11.80x
P/S
1.76x

Upcoming Events

    VYGR Analyst Forecasts

    ‌
    ‌

    VYGR Financials

    VYGR Income Statement Key Metrics

    • Revenue(TTM)163.78 M
    • Gross Profit(TTM)126.80 M
    • EBITDA(TTM)14.13 M
    • Net Income(TTM)25.88 M
    • EPS Diluted(TTM)0.71

    Decode VYGR's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    VYGR earnings and revenue history

    Gross Profit Margin vs Peers

    Profit margin ratio of VYGR (0.982) is higher than the average of its peers (0.293).

    Net Profit Margin vs Peers

    Net profit margin ratio of VYGR (0.529) is higher than the average of its peers (-1.014).

    VYGR Return on Equity

    See how efficiently VYGR generates profit for it's shareholders.

    56.00%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity vs Peers

    Return on Equity ratio of VYGR (0.560) is higher than the average of its peers (-0.836).

    Return on Equity Growth

    VYGR's Return on Equity has grown significantly over the past 10 years, increasing by over 27.63%.

    VYGR Revenue Growth

    See how VYGR has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    VYGR's revenue has grown significantly over the past 10 years, increasing by over 0%.